CD8A and neoplasm: Treatment with CXCR1/2 inhibitor SX-682 dramatically depleted the population of intratumoral CXCR2+ MDSCs and increased the infiltration of CD8+ and CD4+ T cells to suppress pancreatic cancer growth in a mouse iKRAS PDAC model, enhancing the survival time of tumor-bearing mice [98].